13F Holdings
中文EN

ENDV ENDONOVO THERAPEUTICS, INC.

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 1528172 · Fiscal year ends 12/31

Financial factors as of 2023-09-30 (2023Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,699.9%
TTM net income YoY-40.0%
TTM EPS YoY—
Revenue 3-yr CAGR-5.5%
Net income 3-yr CAGR—

Margins

Gross margin96.2%
Operating margin-1,023.2%
Net margin-1,722.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-388.5%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets2,914.6%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.14x
Accruals ratio-333.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20222022-12-31FY20212021-12-31FY20202020-12-31FY20192019-12-31FY20182018-12-31
Income statement
Revenue$135,355$73,105$165,796$310,164$83,263
Cost of revenue$9,990$14,985$65,369$93,385$12,930
Gross profit$125,365$58,120$100,427$216,779$70,333
R&D expense—$0$3,283$153,126$274,265
Operating income-$3.26M-$2.23M-$2.91M-$3.81M-$4.16M
Interest expense—$941,566$2.08M$17,000—
Pretax income-$18.47M-$3.10M-$395,584-$17.31M-$6.44M
Net income-$18.47M-$3.10M-$395,584-$17.31M-$6.44M
EBITDA-$2.62M-$1.58M-$2.26M-$3.16M-$3.51M
EPS (basic)-0.13-0.05-0.03-24.83-17.76
EPS (diluted)—-0.05-0.03-24.83-17.76
Weighted avg. shares (diluted)—59.84M12.22M697,305362,466
Banking
Net interest income-$1.32M-$941,566-$2.08M-$6.09M-$5.20M
Balance sheet
Cash & equivalents$98$85,936$13,420$18,893$379,151
Receivables—$944$942$22,742$3,345
Current assets$15,822$94,855$46,187$62,555$382,496
PP&E, net——$1,580$5,915$6,727
Intangibles$1.27M$1.91M$2.56M$3.21M$3.85M
Total assets$1.28M$2.01M$2.61M$3.27M$4.24M
Current liabilities$33.38M$17.70M$16.83M$23.62M$15.48M
Long-term debt$7.15M$7.26M$6.84M$6.87M$8.16M
Total debt$7.15M$7.26M$6.84M$6.87M$8.16M
Total liabilities$33.46M$17.78M$16.98M$23.78M$15.63M
Shareholders' equity-$32.18M-$15.77M-$14.37M-$20.50M-$11.39M
Net debt$7.15M$7.17M$6.82M$6.86M$7.78M
Shares outstanding213.23M74.50M24.54M1.19M431,063
Cash flow statement
Operating cash flow-$678,838-$986,584-$741,590-$2.54M-$2.88M
Capital expenditure———$2,594$8,969
Free cash flow———-$2.54M-$2.89M
Investing cash flow———-$2,594-$8,969
Financing cash flow$593,000$1.06M$736,117$2.18M$3.18M
Depreciation & amortization$646,912$648,492$651,247$650,315$650,216
Stock-based compensation$45,000$0$57,400$31,012—

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.